A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

NCT06097390 · Completed

Last updated 2026-05-28

This study tests a new protein-based tablet containing semaglutide in healthy men to measure how the body absorbs the medication over 24 hours.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 121 people

Who can join Ages 18–64 · male only Healthy volunteers accepted.

Timeline Started 2023-09 · est. completion 2024-03

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT06097390 ↗

Description as written by the study sponsor.

In this study, a known medicine called 'semaglutide' will be tested in two different tablet versions. The two tablets differ in the way these have been manufactured. The aim of the study is to investigate the amount of active ingredient in the blood after dosing the different tablet versions. Participants will receive one tablet version for 10 days (first treatment period) and the other version for 10 days (second treatment period). The treatment arm participants will be assigned to is decided by chance. The study will last for about 23 weeks for each participant. The study will enroll healthy male participants.

Treatments tested

Semaglutide Drug

Oral administration

Main thing measured	Adjusted AUC0-24h,sema; adjusted area under the semaglutide plasma concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Healthy Participants
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06097390 ↗